
## **Claudine Berr**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/121961/publications.pdf Version: 2024-02-01



CIALIDINE REDD

#	Article	IF	CITATIONS
1	Late-life cynical hostility is associated with white matter alterations and the risk of Alzheimer's disease. Psychological Medicine, 2022, 52, 3636-3645.	4.5	2
2	Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. Alzheimer's and Dementia, 2022, 18, 676-687.	0.8	8
3	Five-Year Dynamic Prediction of Dementia Using Repeated Measures of Cognitive Tests and a Dependency Scale. American Journal of Epidemiology, 2022, 191, 453-464.	3.4	2
4	Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimer's Research and Therapy, 2022, 14, 12.	6.2	12
5	Air quality improvement and incident dementia: Effects of observed and hypothetical reductions in air pollutant using parametric gâ€computation. Alzheimer's and Dementia, 2022, 18, 2509-2517.	0.8	3
6	Sulcal morphology as cognitive decline predictor in older adults with memory complaints. Neurobiology of Aging, 2022, 113, 84-94.	3.1	1
7	Exposure to ambient air pollution and cognitive decline: Results of the prospective Three-City cohort study. Environment International, 2022, 161, 107118.	10.0	17
8	Outdoor air pollution exposure and cognitive performance: findings from the enrolment phase of the CONSTANCES cohort. Lancet Planetary Health, The, 2022, 6, e219-e229.	11.4	26
9	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
10	Modeling exposure to airborne metals using moss biomonitoring in cemeteries in two urban areas around Paris and Lyon in France. Environmental Pollution, 2022, 303, 119097.	7.5	2
11	Association Between Occupational Exposure to Formaldehyde and Cognitive Impairment. Neurology, 2022, 98, .	1.1	16
12	Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study. Drug Safety, 2021, 44, 565-579.	3.2	6
13	Long-term exposure to ambient air pollution and risk of dementia: Results of the prospective Three-City Study. Environment International, 2021, 148, 106376.	10.0	58
14	Plasma amyloid β levels are driven by genetic variants near <i>APOE, BACE1, APP, PSEN2</i> : A genomeâ€wide association study in over 12,000 nonâ€demented participants. Alzheimer's and Dementia, 2021, 17, 1663-1674.	0.8	20
15	Associations between physical activity types and multi-domain cognitive decline in older adults from the Three-city cohort. PLoS ONE, 2021, 16, e0252500.	2.5	8
16	Socioeconomic inequalities in dementia risk among a French population-based cohort: quantifying the role of cardiovascular health and vascular events. European Journal of Epidemiology, 2021, 36, 1015-1023.	5.7	7
17	Frailty in Aging People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, 305-309.	2.1	5
18	Dynamic reciprocal relationships between cognitive and functional declines along the Alzheimer's disease continuum in the prospective COGICARE study. Alzheimer's Research and Therapy, 2021, 13, 148.	6.2	3

#	Article	IF	CITATIONS
19	Similarities in cognitive abilities in older couples: a study of mutual influences. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 78-90.	1.3	4
20	Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55–70 Study. Clinical Infectious Diseases, 2020, 70, 2641-2648.	5.8	19
21	Association of anthropometry and weight change with risk of dementia and its major subtypes: A metaâ€analysis consisting 2.8 million adults with 57 294 cases of dementia. Obesity Reviews, 2020, 21, e12989.	6.5	62
22	Individual and neighbourhood socioeconomic inequalities in cognitive impairment: cross-sectional findings from the French CONSTANCES cohort. BMJ Open, 2020, 10, e033751.	1.9	10
23	Geneâ€diet interaction and dementia risk: The example of coffee and CYP1A2 gene. Alzheimer's and Dementia, 2020, 16, e039850.	0.8	2
24	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
25	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
26	Twenty-seven-year time trends in dementia incidence in Europe and the United States. Neurology, 2020, 95, e519-e531.	1.1	227
27	Association between occupational solvent exposure and cognitive performance in the French CONSTANCES study. Occupational and Environmental Medicine, 2020, 77, 223-230.	2.8	7
28	Occupational Determinants of Cognitive Decline and Dementia. , 2020, , 235-249.		2
29	Sex-specific depressive symptoms as markers of pre-Alzheimer dementia: findings from the Three-City cohort study. Translational Psychiatry, 2019, 9, 291.	4.8	11
30	Diabetes-Associated Dementia Risk and Competing Risk of Death in the Three-City Study. Journal of Alzheimer's Disease, 2019, 71, 1339-1350.	2.6	6
31	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. Frontiers in Neurology, 2019, 10, 989.	2.4	18
32	Intake of Meat, Fish, Fruits, and Vegetables and Long-Term Risk of Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 711-722.	2.6	26
33	Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. American Journal of Clinical Nutrition, 2019, 109, 1216-1223.	4.7	39
34	Influence of activity space on the association between neighborhood characteristics and dementia risk: results from the 3-City study cohort. BMC Geriatrics, 2019, 19, 4.	2.7	12
35	Health administrative data enrichment using cohort information: Comparative evaluation of methods by simulation and application to real data. PLoS ONE, 2019, 14, e0211118.	2.5	1
36	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962

#	Article	IF	CITATIONS
37	Socioeconomic inequalities in cognitive performance among early ageing people: The Constances cohort. European Journal of Public Health, 2019, 29, .	0.3	0
38	Long-term effects of compulsory schooling on physical, mental and cognitive ageing: a natural experiment. Journal of Epidemiology and Community Health, 2019, 73, 370-376.	3.7	28
39	Norms for standard neuropsychological tests from the French <scp>CONSTANCES</scp> cohort. European Journal of Neurology, 2019, 26, 786-793.	3.3	17
40	Vision loss and 12-year risk of dementia in older adults: the 3C cohort study. European Journal of Epidemiology, 2019, 34, 141-152.	5.7	53
41	Occupational Determinants of Cognitive Decline and Dementia. , 2019, , 1-15.		1
42	Near Visual Impairment Incidence in Relation to Diabetes in Older People: The Three ities Study. Journal of the American Geriatrics Society, 2018, 66, 699-705.	2.6	5
43	Amyloid Angiopathy in Brain Hemorrhage: A Postmortem Neuropathological-Magnetic Resonance Imaging Study. Cerebrovascular Diseases, 2018, 45, 124-131.	1.7	28
44	Fish Intake, Genetic Predisposition to Alzheimer Disease, and Decline in Global Cognition and Memory in 5 Cohorts of Older Persons. American Journal of Epidemiology, 2018, 187, 933-940.	3.4	61
45	Sexâ€specific association between neighborhood characteristics and dementia: The Three ity cohort. Alzheimer's and Dementia, 2018, 14, 473-482.	0.8	29
46	P3â€624: PRIMARY DEMENTIA PREVENTION: RECOMMENDATIONS FOR FRENCH PUBLIC HEALTH POLICY. Alzheimer's and Dementia, 2018, 14, P1370.	0.8	0
47	P3â€274: COMBINATION OF A FUNCTIONAL SYNAPTIC BIOMARKER (ERP) AND VERBAL FLUENCY TEST TO SELECT AMYLOID POSITIVE ELDERLY SUBJECTS IN CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P1182.	Г <sub>О.8</sub>	0
48	P3â€596: VISUAL LOSS AND COGNITIVE DECLINE IN OLDER ADULTS: RESULTS FROM A FRENCH POPULATIONâ€BASED COHORT STUDY. Alzheimer's and Dementia, 2018, 14, P1355.	0.8	2
49	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	2.4	2
50	Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1107-1115.	1.9	24
51	Evaluation of the Concurrent Trajectories of Cardiometabolic Risk Factors in the 14 Years Before Dementia. JAMA Psychiatry, 2018, 75, 1033.	11.0	56
52	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
53	Anxiety and 10-Year Risk of Incident Dementia—An Association Shaped by Depressive Symptoms: Results of the Prospective Three-City Study. Frontiers in Neuroscience, 2018, 12, 248.	2.8	17
54	Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia. JAMA - Journal of the American Medical Association, 2018, 320, 657.	7.4	180

#	Article	IF	CITATIONS
55	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics, 2018, 50, 524-537.	21.4	1,124
56	Dynamic prediction models for clustered and interval-censored outcomes: Investigating the intra-couple correlation in the risk of dementia. Statistical Methods in Medical Research, 2017, 26, 2168-2183.	1.5	12
57	Gender effect on driving cessation in pre-dementia and dementia phases: results of the 3C population-based study. International Journal of Geriatric Psychiatry, 2017, 32, 1049-1058.	2.7	7
58	Ideal Cardiovascular Health, Mortality, andÂVascular Events in Elderly Subjects. Journal of the American College of Cardiology, 2017, 69, 3015-3026.	2.8	125
59	Orthostatic Hypotension and Risk of Incident Dementia. Hypertension, 2017, 70, 44-49.	2.7	42
60	Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. Journal of Alzheimer's Disease, 2017, 58, 87-97.	2.6	4
61	Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population. Alzheimer's Research and Therapy, 2017, 9, 21.	6.2	15
62	Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. European Journal of Epidemiology, 2017, 32, 931-938.	5.7	23
63	Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39†740 adults from 20 prospective cohort studies. Lancet Diabetes and Endocrinology,the, 2017, 5, 965-974.	11.4	213
64	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
65	Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease. Kidney International Reports, 2017, 2, 180-191.	0.8	3
66	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Frontiers in Aging Neuroscience, 2017, 9, 312.	3.4	26
67	Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer's Disease. Current Alzheimer Research, 2017, 14, 255-267.	1.4	2
68	Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?. Journal of Alzheimer's Disease, 2016, 49, 1135-1141.	2.6	7
69	Kidney Function Decline and Apparent Treatment-Resistant Hypertension in the Elderly. PLoS ONE, 2016, 11, e0146056.	2.5	11
70	Domains of cognitive function in early old age: which ones are predicted by pre-retirement psychosocial work characteristics?. Occupational and Environmental Medicine, 2016, 73, 640-647.	2.8	29
71	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. International Psychogeriatrics, 2016, 28, 707-717.	1.0	96
72	O1â€02â€05: Presbycusis and Dementia: Results From 8 Years of Followâ€Up in the Three ity Montpellier Study. Alzheimer's and Dementia, 2016, 12, P175.	0.8	1

#	Article	IF	CITATIONS
73	Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 921-932.	2.6	77
74	Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2016, 15, 695-707.	10.2	130
75	Nutrition and mortality in the elderly over 10 years of follow-up: the Three-City study. British Journal of Nutrition, 2016, 116, 882-889.	2.3	23
76	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
77	Effect size for the main cognitive function determinants in a large crossâ€sectional study. European Journal of Neurology, 2016, 23, 1614-1626.	3.3	13
78	Are migraine and nonâ€migrainous headache risk factors for stroke in the elderly? Findings from a 12â€year cohort followâ€up. European Journal of Neurology, 2016, 23, 1463-1470.	3.3	16
79	ADL disability and death in dementia in a French population-based cohort: New insights with an illness-death model. , 2016, 12, 909-916.		9
80	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. EBioMedicine, 2016, 9, 278-292.	6.1	40
81	The APOE epsilon 4 polymorphism does not predict late onsetÂdepression: the Three-City Study. Neurobiology of Aging, 2016, 40, 191.e9-191.e10.	3.1	5
82	Impact of sleep disturbances on kidney function decline in the elderly. European Respiratory Journal, 2016, 47, 860-868.	6.7	18
83	How to optimize the use of biobanks from population-based cohorts in aging research. Biogerontology, 2016, 17, 221-227.	3.9	4
84	Benzodiazepine, psychotropic medication, and dementia: AÂpopulationâ€based cohort study. Alzheimer's and Dementia, 2016, 12, 604-613.	0.8	69
85	Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1356-1362.	3.6	13
86	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
87	The Clinical Picture of Alzheimer's Disease in the Decade Before Diagnosis. Journal of Clinical Psychiatry, 2016, 77, e305-e311.	2.2	50
88	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Aging,the, 2016, 5, 1-9.	1.3	8
89	Effect of Early Referral to Specialist in Dementia on Institutionalization and Functional Decline: Findings from a Population-Based Study. Journal of Alzheimer's Disease, 2015, 49, 819-828.	2.6	12
90	Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics. Journal of Alzheimer's Disease, 2015, 49, 1075-1083.	2.6	3

#	Article	IF	CITATIONS
91	O1â€09â€04: Community environment and incident dementia: Results from the three ity study. Alzheimer's and Dementia, 2015, 11, P150.	0.8	2
92	O2-03-05: Fish intake, Alzheimer disease genes, and cognitive decline in five cohorts of older subjects. , 2015, 11, P179-P179.		0
93	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. Journal of Nutrition, Health and Aging, 2015, 19, 955-960.	3.3	85
94	Developmental determinants in non-communicable chronic diseases and ageing. Thorax, 2015, 70, 595-597.	5.6	45
95	Quantifying and Comparing Dynamic Predictive Accuracy of Joint Models for Longitudinal Marker and Time-to-Event in Presence of Censoring and Competing Risks. Biometrics, 2015, 71, 102-113.	1.4	92
96	Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53 949). Molecular Psychiatry, 2015, 20, 183-192.	7.9	344
97	Operative definition of active and healthy ageing (AHA): Meeting report. Montpellier October 20–21, 2014. European Geriatric Medicine, 2015, 6, 196-200.	2.8	18
98	Elderly Benzodiazepine Users at Increased Risk of Activity Limitations: Influence of Chronicity, Indications, and Duration of Action—The Three-City Cohort. American Journal of Geriatric Psychiatry, 2015, 23, 840-851.	1.2	19
99	PLD3 and sporadic Alzheimer's disease risk. Nature, 2015, 520, E1-E1.	27.8	54
100	Poor nutritional status is associated with a higher risk of falling and fracture in elderly people living at home in France: the Three-City cohort study. Osteoporosis International, 2015, 26, 2157-2164.	3.1	37
101	Survival and early recourse to care for dementia: A population based study. Alzheimer's and Dementia, 2015, 11, 385-393.	0.8	19
102	Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism. American Journal of Human Genetics, 2015, 96, 532-542.	6.2	222
103	Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 20–21, 2014, Lisbon July 2, 2015. Journal of the American Medical Directors Association, 2015, 16, 1020-1026.	2.5	33
104	Plasma βâ€amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimer's and Dementia, 2015, 11, 672-680.	0.8	21
105	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
106	Nutritional Status in Community-Dwelling Elderly in France in Urban and Rural Areas. PLoS ONE, 2014, 9, e105137.	2.5	38
107	Measuring cognitive change in subjects with prodromal Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 363-370.	1.9	50
108	Normalized Mini-Mental State Examination for Assessing Cognitive Change in Population-Based Brain Aging Studies. Neuroepidemiology, 2014, 43, 15-25.	2.3	58

#	Article	IF	CITATIONS
109	Metabolic Syndrome and Disability: Findings From the Prospective Three-City Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 79-86.	3.6	47
110	Plasma lipids and cerebral small vessel disease. Neurology, 2014, 83, 1844-1852.	1.1	61
111	Impact of a premature menopause on cognitive function in later life. BJOC: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1729-1739.	2.3	140
112	Time may not fully attenuate solvent-associated cognitive deficits in highly exposed workers. Neurology, 2014, 82, 1716-1723.	1.1	24
113	Education Modulates the Impact of White Matter Lesions on the Risk of Mild Cognitive Impairment and Dementia. American Journal of Geriatric Psychiatry, 2014, 22, 1336-1345.	1.2	55
114	Gender-specific associations between lipids and cognitive decline in the elderly. European Neuropsychopharmacology, 2014, 24, 1056-1066.	0.7	46
115	Perception of Alzheimer's disease in the French population. Journal of Nutrition, Health and Aging, 2014, 18, 393-399.	3.3	22
116	MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on) Tj ETQo	0.0 0 rgB <sup>−</sup> 2.8 2.9 2.0 י	T /Qyerlock 1(
117	Hierarchical structure of the activities of daily living scale in dementia. Journal of Nutrition, Health and Aging, 2014, 18, 698-704.	3.3	12
118	A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. Molecular Psychiatry, 2014, 19, 1326-1335.	7.9	36
119	Estrogen receptor polymorphisms and incident dementia: The prospective 3C study. Alzheimer's and Dementia, 2014, 10, 27-35.	0.8	32
120	Subjective cognitive complaints and mortality: Does the type of complaint matter?. Journal of Psychiatric Research, 2014, 48, 73-78.	3.1	63
121	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
122	Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Molecular Psychiatry, 2013, 18, 1225-1234.	7.9	321
123	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
124	Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Medicine, 2013, 11, 212.	5.5	64
125	<i>TREM2</i> Variants in Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 117-127.	27.0	2,385
126	Chronic use of benzodiazepines and latent cognitive decline in the elderly: Results from the Three-city study. European Neuropsychopharmacology, 2013, 23, 212-223.	0.7	54

#	Article	IF	CITATIONS
127	Prospective analysis of the association between estrogen receptor gene variants and the risk of cognitive decline in elderly women. European Neuropsychopharmacology, 2013, 23, 1763-1768.	0.7	19
128	A prospective study of the bi-directional association between vision loss and depression in the elderly. Journal of Affective Disorders, 2013, 151, 164-170.	4.1	79
129	A Simple Score to Predict Survival with Dementia in the General Population. Neuroepidemiology, 2013, 41, 20-28.	2.3	10
130	Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. Journal of Lipid Research, 2013, 54, 2559-2567.	4.2	38
131	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Molecular Psychiatry, 2013, 18, 461-470.	7.9	103
132	Caffeine and Cognitive Decline in Elderly Women at High Vascular Risk. Journal of Alzheimer's Disease, 2013, 35, 413-421.	2.6	51
133	Sex Differences in the Associations Between Lipid Levels and Incident Dementia. Journal of Alzheimer's Disease, 2013, 34, 519-528.	2.6	69
134	Spatial Distribution of Cerebral White Matter Lesions Predicts Progression to Mild Cognitive Impairment and Dementia. PLoS ONE, 2013, 8, e56972.	2.5	35
135	Gender Differences in the Association between Socioeconomic Status and Subclinical Atherosclerosis. PLoS ONE, 2013, 8, e80195.	2.5	15
136	Occupational solvent exposure and cognition. Neurology, 2012, 78, 1754-1760.	1.1	30
137	Excessive Sleepiness is Predictive of Cognitive Decline in the Elderly. Sleep, 2012, 35, 1201-1207.	1.1	178
138	Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study. Journal of Alzheimer's Disease, 2012, 30, 629-637.	2.6	66
139	Authors' reply to Harwood, McCarthy, and Franke. BMJ: British Medical Journal, 2012, 344, e1050-e1050.	2.3	1
140	High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Molecular Psychiatry, 2012, 17, 875-879.	7.9	253
141	Abdominal Obesity and Lateâ€Onset Asthma: Crossâ€Sectional and Longitudinal Results: The 3C Study. Obesity, 2012, 20, 628-635.	3.0	32
142	Single polymorphism nucleotide rs1333049 on chromosome 9p21 is associated with carotid plaques but not with common carotid intima-media thickness in older adults. A combined analysis of the Three-City and the EVA studies. Atherosclerosis, 2012, 222, 187-190.	0.8	9
143	Metabolic syndrome and localization of white matter hyperintensities in the elderly population. , 2012, 8, S88-S95.e1.		33
144	Anxiety symptoms and disorder predict activity limitations in the elderly. Journal of Affective Disorders, 2012, 141, 276-285.	4.1	40

#	Article	IF	CITATIONS
145	Plasma Amyloid-β Levels and Prognosis in Incident Dementia Cases of the 3-City Study. Journal of Alzheimer's Disease, 2012, 33, 381-391.	2.6	21
146	Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. Neurobiology of Aging, 2012, 33, 2082-2090.	3.1	27
147	Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus. Neurobiology of Aging, 2012, 33, 1848.e1-1848.e13.	3.1	5
148	Mediterranean Diet and Cognitive Decline in Women with Cardiovascular Disease or Risk Factors. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 816-823.	0.8	87
149	Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ: British Medical Journal, 2012, 344, d7622-d7622.	2.3	610
150	P-620 - Anxiety: a risk factor for the incidence of activity limitations in the elderly. European Psychiatry, 2012, 27, 1.	0.2	0
151	Selenium and cognitive impairment: A briefâ€review based on results from the EVA study. BioFactors, 2012, 38, 139-144.	5.4	61
152	High alcohol consumption in middle-aged adults is associated with poorer cognitive performance only in the low socio-economic group. Results from the GAZEL cohort study. Addiction, 2011, 106, 93-101.	3.3	23
153	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
154	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	7.9	529
155	Late life depression and incident activity limitations: Influence of gender and symptom severity. Journal of Affective Disorders, 2011, 133, 42-50.	4.1	34
156	Chronic kidney disease, cognitive decline, and incident dementia. Neurology, 2011, 77, 2043-2051.	1.1	151
157	Alternative Healthy Eating Index and mortality over 18 y of follow-up: results from the Whitehall II cohort. American Journal of Clinical Nutrition, 2011, 94, 247-253.	4.7	151
158	Epidemiology and prognostic significance of chronic kidney disease in the elderly—the Three-City prospective cohort study. Nephrology Dialysis Transplantation, 2011, 26, 3286-3295.	0.7	99
159	Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney functionthe Three-City population-based study. Nephrology Dialysis Transplantation, 2011, 26, 2852-2859.	0.7	84
160	Olive oil consumption, plasma oleic acid, and stroke incidence. Neurology, 2011, 77, 418-425.	1.1	115
161	Self-rated health and risk of incident dementia. Neurology, 2011, 77, 1457-1464.	1.1	49
162	Metabolic Syndrome and Onset of Depressive Symptoms in the Elderly. Diabetes Care, 2011, 34, 904-909.	8.6	56

#	Article	IF	CITATIONS
163	Association of Plasma Aß Peptides with Blood Pressure in the Elderly. PLoS ONE, 2011, 6, e18536.	2.5	19
164	Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis. Journal of Alzheimer's Disease, 2010, 20, 1107-1118.	2.6	152
165	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
166	Systematic Analysis of Candidate Genes for Alzheimer's Disease in a French, Genome-Wide Association Study. Journal of Alzheimer's Disease, 2010, 20, 1181-1188.	2.6	63
167	Neurodegenerative dementia and Parkinsonism. Journal of Nutrition, Health and Aging, 2010, 14, 37-44.	3.3	6
168	Plasma selenium and risk of dysglycemia in an elderly French population: results from the prospective Epidemiology of Vascular Ageing Study. Nutrition and Metabolism, 2010, 7, 21.	3.0	103
169	Validation study of a French version of the modified telephone interview for cognitive status (Fâ€IICSâ€m) in elderly women. International Journal of Geriatric Psychiatry, 2010, 25, 1142-1149.	2.7	33
170	How many dementia cases in France and Europe? Alternative projections and scenarios 2010–2050. European Journal of Neurology, 2010, 17, 252-259.	3.3	80
171	Is the Urea Cycle Involved in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2010, 21, 1013-1021.	2.6	68
172	Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1832.	7.4	1,064
173	Occupational Exposure to Solvents and Cognitive Performance in the GAZEL Cohort: Preliminary Results. Dementia and Geriatric Cognitive Disorders, 2010, 30, 12-19.	1.5	21
174	Validity of the Free and Cued Selective Reminding Test in predicting dementia. Neurology, 2010, 74, 1760-1767.	1.1	75
175	Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ: British Medical Journal, 2010, 341, c3885-c3885.	2.3	181
176	Metabolic Syndrome, Its Components, and Mortality in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E327-E332.	3.6	28
177	Retrospective Identification and Characterization of Mild Cognitive Impairment From a Prospective Population Cohort. American Journal of Geriatric Psychiatry, 2010, 18, 692-700.	1.2	25
178	Association study of the CFH Y402H polymorphism with Alzheimer's disease. Neurobiology of Aging, 2010, 31, 165-166.	3.1	27
179	Olive Oil and Cognition: Results from the Three-City Study. Dementia and Geriatric Cognitive Disorders, 2009, 28, 357-364.	1.5	122
180	Leisure activities and the risk of dementia in the elderly. Neurology, 2009, 73, 854-861.	1.1	263

#	Article	IF	CITATIONS
181	Increased selenium intake in elderly high fish consumers may account for health benefits previously ascribed to omega-3 fatty acids. Journal of Nutrition, Health and Aging, 2009, 13, 14-18.	3.3	40
182	Early detection of patients in the pre demented stage of Alzheimer's disease: The Pre-Al study. Journal of Nutrition, Health and Aging, 2009, 13, 21-26.	3.3	18
183	Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease. Molecular Psychiatry, 2009, 14, 106-116.	7.9	43
184	Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Molecular Psychiatry, 2009, 14, 1004-1016.	7.9	167
185	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
186	Fibrates but not statins increase plasma selenium in dyslipidemic aged patients – The EVA study. Journal of Trace Elements in Medicine and Biology, 2009, 23, 21-28.	3.0	18
187	Total plasma carotenoids and mortality in the elderly: results of the Epidemiology of Vascular Ageing (EVA) study. British Journal of Nutrition, 2009, 101, 86-92.	2.3	48
188	Metabolic Syndrome and Risk for Incident Alzheimer's Disease or Vascular Dementia. Diabetes Care, 2009, 32, 169-174.	8.6	277
189	Association of plasma amyloid $\hat{I}^2$ with risk of dementia. Neurology, 2009, 73, 847-853.	1.1	126
190	Long-term association of food and nutrient intakes with cognitive and functional decline: a 13-year follow-up study of elderly French women. British Journal of Nutrition, 2009, 102, 419-427.	2.3	142
191	Performance of a short dietary questionnaire to assess nutrient intake using regression-based weights. Public Health Nutrition, 2009, 12, 547.	2.2	4
192	Prevention of progression to dementia in the elderly: Rationale and proposal for a health-promoting memory consultation (an IANA task force). Journal of Nutrition, Health and Aging, 2008, 12, 520-529.	3.3	23
193	Importance of Lack of Interest in Patients With Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2008, 16, 770-776.	1.2	81
194	Plasma Carotenoids and Onset of Dysglycemia in an Elderly Population. Diabetes Care, 2008, 31, 1355-1359.	8.6	39
195	Risk profiles for mild cognitive impairment and progression to dementia are gender specific. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 979-984.	1.9	222
196	Haplotypes Across ACE and the Risk of Alzheimer's Disease: The Three-City Study. Journal of Alzheimer's Disease, 2008, 13, 333-339.	2.6	13
197	Pure-Tone Threshold Description of an Elderly French Screened Population. Otology and Neurotology, 2008, 29, 432-440.	1.3	16
198	Amnestic syndrome of the medial temporal type identifies prodromal AD. Neurology, 2007, 69, 1859-1867.	1.1	425

#	Article	IF	CITATIONS
199	Dietary patterns and risk of dementia. Neurology, 2007, 69, 1921-1930.	1.1	630
200	Plasma Carotenoid Levels and Cognitive Performance in an Elderly Population: Results of the EVA Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 308-316.	3.6	103
201	Differential Dietary Nutrient Intake according to Hormone Replacement Therapy Use: An Underestimated Confounding Factor in Epidemiologic Studies?. American Journal of Epidemiology, 2007, 166, 1451-1460.	3.4	4
202	Plasma Selenium Over Time and Cognitive Decline in the Elderly. Epidemiology, 2007, 18, 52-58.	2.7	147
203	Evidence of a Role for Lactadherin in Alzheimer's Disease. American Journal of Pathology, 2007, 170, 921-929.	3.8	94
204	Factors associated with longitudinal plasma selenium decline in the elderly: The EVA Study. Journal of Nutritional Biochemistry, 2007, 18, 482-487.	4.2	62
205	Evidence for the association of the S100β gene with low cognitive performance and dementia in the elderly. Molecular Psychiatry, 2007, 12, 870-880.	7.9	26
206	IANA task force on nutrition and cognitive decline with aging. Journal of Nutrition, Health and Aging, 2007, 11, 132-52.	3.3	180
207	Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease. Clinical Neurology and Neurosurgery, 2006, 108, 733-736.	1.4	182
208	Peroxydation lipidique et vieillissement cérébralÂ: l'apport des études épidémiologiques. Oleagine Corps Gras Lipides, 2006, 13, 54-58.	2ux 0.2	2
209	Neuropsychological Performance in Mild Cognitive Impairment with and without Apathy. Dementia and Geriatric Cognitive Disorders, 2006, 21, 192-197.	1.5	71
210	Characteristics of tinnitus in a population of 555 patients: specificities of tinnitus induced by noise trauma. International Tinnitus Journal, 2006, 12, 64-70.	0.2	38
211	Incidence and Characteristics of Benzodiazepine Use in an Elderly Cohort: The EVA Study. Therapie, 2005, 60, 561-566.	1.0	13
212	Neuroprotection and Neurodegenerative Diseases. Alzheimer Disease and Associated Disorders, 2005, 19, 226-239.	1.3	27
213	Cost of dementia in Europe. European Journal of Neurology, 2005, 12, 50-53.	3.3	42
214	Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study. European Journal of Clinical Nutrition, 2005, 59, 817-825.	2.9	112
215	Frequency and risk factors of potentially inappropriate medication use in a community-dwelling elderly population: results from the 3C Study. European Journal of Clinical Pharmacology, 2005, 60, 813-819.	1.9	101
216	Neuropsychological predictors of dependency in patients with Alzheimer disease. Neurology, 2005, 64, 1027-1031.	1.1	35

#	Article	IF	CITATIONS
217	Selenium and Mortality in the Elderly: Results from the EVA Study. Clinical Chemistry, 2005, 51, 2117-2123.	3.2	168
218	Prevalence of dementia in the elderly in Europe. European Neuropsychopharmacology, 2005, 15, 463-471.	0.7	187
219	O4-4 CaroténoÃ⁻des et performances cognitives chez le sujet âgé : Résultats de l'étude EVA. Revue Neurologique, 2005, 161, 72-73.	1.5	0
220	Estimated numbers of postmenopausal women treated by hormone therapy in France. Maturitas, 2005, 52, 296-305.	2.4	28
221	C8-3 Vers une prévention primaire : hormonothérapie à la ménopause et démence. Revue Neurologique, 2005, 161, 54-55.	1.5	0
222	Relationship between body mass index and different domains of disability in older persons: the 3C study. International Journal of Obesity, 2004, 28, 1555-1560.	3.4	101
223	Estimated number of women likely to benefit from bone mineral density measurement in France. Joint Bone Spine, 2004, 71, 409-418.	1.6	13
224	Estimation du nombre de femmes françaises à risque d'ostéoporose susceptibles de bénéficier d'ı ostéodensitométrie. Revue Du Rhumatisme (Edition Francaise), 2004, 71, 790-800.	une 0.0	4
225	Carcinome de l'ethmoÃ⁻de chez un patient fabriquant des semelles de chaussures orthopédiques en liege. Archives Des Maladies Professionnelles Et De L'Environnement, 2004, 65, 25-29.	0.1	0
226	Paraoxonase 1 gene polymorphisms and dementia in humans. Neuroscience Letters, 2004, 358, 41-44.	2.1	31
227	APOE promoter polymorphisms and dementia in the elderly. Neuroscience Letters, 2004, 365, 116-119.	2.1	9
228	Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women. Journal of Hypertension, 2004, 22, 739-743.	0.5	37
229	Sociodemographic differences in dietary habits in a population-based sample of elderly subjects: the 3C study. Journal of Nutrition, Health and Aging, 2004, 8, 497-502.	3.3	38
230	Enzymatic antioxidant balance and cognitive decline in aging – the EVA study. European Journal of Epidemiology, 2003, 19, 133-138.	5.7	28
231	Polymorphism of the codon 129 of the prion protein (PrP) gene and neuropathology of cerebral ageing. Acta Neuropathologica, 2003, 106, 71-74.	7.7	26
232	Effects of lipid peroxidation and antioxidant status on peak flow in a population aged 59–71 years: the EVA study. Respiratory Medicine, 2003, 97, 939-946.	2.9	7
233	Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study. American Journal of Clinical Nutrition, 2003, 77, 803-808.	4.7	327
234	Épidémiologie de la maladie d'Alzheimer. Medecine/Sciences, 2002, 18, 737-743.	0.2	10

#	Article	IF	CITATIONS
235	Orosomucoid: a mortality risk factor in elderly people living in the community?. Clinical Nutrition, 2002, 21, 45-50.	5.0	16
236	Oxidative stress and cognitive impairment in the elderly. Journal of Nutrition, Health and Aging, 2002, 6, 261-6.	3.3	25
237	Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiology of Aging, 2001, 22, 227-235.	3.1	19
238	Plasma Insulin-Like Growth Factor I Levels in the Elderly: Relation to Plasma Dehydroepiandrosterone Sulfate Levels, Nutritional Status, Health and Mortality. Gerontology, 2001, 47, 198-206.	2.8	27
239	Changes in Cognitive Abilities Over a 4-Year Period Are Unfavorably Affected in Elderly Diabetic Subjects. Diabetes Care, 2001, 24, 366-370.	8.6	275
240	Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: Relationship to gender, subjective health, smoking habits, and 10-year mortality. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8145-8150.	7.1	151
241	VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology, 2001, 56, 1183-1188.	1.1	28
242	Cognitive Decline Is Associated with Systemic Oxidative Stress: The EVA Study. Journal of the American Geriatrics Society, 2000, 48, 1285-1291.	2.6	246
243	The Renin Angiotensin System and Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 437-441.	3.8	62
244	Cognitive impairment and oxidative stress in the elderly: Results of epidemiological studies. BioFactors, 2000, 13, 205-209.	5.4	54
245	Common Carotid Intima-Media Thickness Predicts Occurrence of Carotid Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1622-1629.	2.4	218
246	Effect of the angiotensin l-converting enzyme I/D polymorphism on cognitive declineâ~†. Neurobiology of Aging, 2000, 21, 75-80.	3.1	40
247	Influence of Apolipoprotein E Genotype on the Risk of Cognitive Deterioration in Moderate Drinkers and Smokers. Epidemiology, 2000, 11, 280-284.	2.7	110
248	Risk of dementia in parents of probands with and without the apolipoprotein E4 allele. The EVA study. Journal of Epidemiology and Community Health, 1999, 53, 393-398.	3.7	2
249	Is the LDL receptor-related protein involved in Alzheimer's disease?. Neurogenetics, 1999, 2, 109-113.	1.4	29
250	Cross-Sectional and 4-Year Longitudinal Associations Between Brachial Pulse Pressure and Common Carotid Intima-Media Thickness in a General Population. Stroke, 1999, 30, 550-555.	2.0	122
251	Systemic Oxidative Stress and Cognitive Performance in the Population-Based EVA Study. Free Radical Biology and Medicine, 1998, 24, 1202-1208.	2.9	60
252	Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Human Molecular Genetics, 1998, 7, 1511-1516.	2.9	127

#	Article	IF	CITATIONS
253	Polymorphism of the prion protein is associated with cognitive impairment in the elderly. Neurology, 1998, 51, 734-737.	1.1	71
254	Demographic and cardiovascular risk factors in relation to antioxidant status: the EVA Study. International Journal for Vitamin and Nutrition Research, 1998, 68, 26-35.	1.5	25
255	Combined effects of lipid peroxidation and antioxidant status on carotid atherosclerosis in a population aged 59ß71 y: The EVA Study. Etude sur le Vieillisement Artériel. American Journal of Clinical Nutrition, 1997, 65, 121-127.	4.7	95
256	Relationships of Dehydroepiandrosterone Sulfate in the Elderly With Functional, Psychological, and Mental Status, and Short-Term Mortality. Obstetrical and Gynecological Survey, 1997, 52, 238-240.	0.4	0
257	Early effect of ApoE-ïµ4 allele on cognitive results in a group of highly performing subjects: the EVA study. Neuroscience Letters, 1996, 218, 9-12.	2.1	69
258	Relation of serum elastase activity to ultrasonographically assessed carotid artery wall lesions and cardiovascular risk factors. The EVA study. Atherosclerosis, 1996, 120, 47-55.	0.8	45
259	Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: A French community-based study. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 13410-13415.	7.1	267
260	Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type—Place of the extracellular glutathione peroxidase. Free Radical Biology and Medicine, 1996, 20, 579-587.	2.9	119
261	Aromatic polypyromellitimides from aromatic polyamic acids. Journal of Polymer Science Part A, 1996, 34, 2069-2086.	2.3	18
262	Relation of Intima-Media Thickness to Atherosclerotic Plaques in Carotid Arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 310-316.	2.4	219
263	Factors of Carotid Arterial Enlargement in a Population Aged 59 to 71 Years. Stroke, 1996, 27, 654-660.	2.0	110
264	Ultrasonographic Assessment of Carotid Wall Characteristics and Cognitive Functions in a Community Sample of 59- to 71-Year-Olds. Stroke, 1996, 27, 1290-1295.	2.0	72
265	Dehydroepiandrosterone Sulfate in a Long-term Care Aged Population. Gerontology, 1995, 41, 343-351.	2.8	76
266	Apolipoprotein E, É>4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Human Molecular Genetics, 1994, 3, 569-574.	2.9	400
267	Apolipoprotein E allele ε4 is linked to increased deposition of the amyloid β-peptide (A-β) in cases with or without Alzheimer's disease. Neuroscience Letters, 1994, 178, 221-224.	2.1	80
268	Confirmation of the ϵ4 allele of the apolipoprotein E gene as a risk factor for lateâ€onset Alzheimer's disease. Neurology, 1994, 44, 342-342.	1.1	100
269	Cognitive performance and three-year mortality in the PAQUID elderly study. Revue D'Epidemiologie Et De Sante Publique, 1994, 42, 277-84.	0.5	9
270	Selenium and Oxygenâ€Metabolizing Enzymes in Elderly Community Residents: A Pilot Epidemiological Study. Journal of the American Geriatrics Society, 1993, 41, 143-148.	2.6	56

#	Article	IF	CITATIONS
271	Loss of Calcium-Homeostatic Mechanisms in Polymorphonuclear Leukocytes of Demented and Nondemented Elderly Subjects. Gerontology, 1993, 39, 163-169.	2.8	19
272	Dermatoglyphic patterns in dementia of the Alzheimer type: a case-control study Journal of Epidemiology and Community Health, 1992, 46, 512-516.	3.7	2
273	Validation of a questionnaire to detect dementia cases in families. Neurobiology of Aging, 1992, 13, S117-S118.	3.1	1
274	Association between plasma selenium concentration and cognitive functioning in elderly community residents. Neurobiology of Aging, 1992, 13, S96.	3.1	0
275	Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls. Human Immunology, 1991, 31, 94-99.	2.4	8
276	Dermatoglyphics as a possible genetic marker in dementia of Alzheimer type: A case-control study. Neurobiology of Aging, 1990, 11, 295.	3.1	2
277	Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. Acta Neurologica Scandinavica, 1989, 80, 46-50.	2.1	77
278	Absence of familial association between dementia of Alzheimer type and down syndrome. American Journal of Medical Genetics Part A, 1989, 33, 545-550.	2.4	13
279	Immunoglobulin allotypes and susceptibility to multiple sclerosis. Journal of the Neurological Sciences, 1986, 75, 1-5.	0.6	19